TGFB1 and hepatocellular carcinoma: Of note, the TGF‐β inhibitor, LY2157299 (galunisertib), is in phase II studies against glioblastoma and hepatocellular carcinoma (Brandes et al., 2016; Giannelli et al., 2016; Rodon et al., 2015).